Ardent Health Issues FY 2026 Guidance; Aptiv Reports Q2 Results

Ardent Health (NYSE: ARDT) updated its fiscal‑year‑2026 outlook, projecting earnings per share of $0.78‑$1.15 and revenue between $6.4 billion and $6.7 billion, both below analyst consensus. The company’s shares traded around $10.74 after the announcement.

Aptiv (NYSE: APTV) posted second‑quarter 2024 results with revenue of $3.3 billion, a 2% adjusted increase, and adjusted EBITDA of $613 million. Earnings per share were $1.63, up $0.12 year‑over‑year. The automaker noted weaker demand in China’s domestic market and reduced production schedules from European luxury OEMs, while non‑automotive revenue grew 12%. Free cash flow was a $33 million outflow, largely due to cash‑separation costs from the Versigent spinoff.